Parnax Lab

Parnax Lab CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Parnax Lab (506128.BO) as of Nov 3, 2026 is 57.51 %. In the previous year, CapEx to Operating Cash Flow Ratio was 204.66 % — a change of -71.90% (lower).

CapEx/OCF

57.51 %

YoY

-71.90%

Last updated:

CapEx to Operating Cash Flow Ratio of Parnax Lab is 2025 57.51 % . CapEx to Operating Cash Flow Ratio of Parnax Lab was 2024 204.66 % . It decreases by -71.90% lower compared to the previous year.

The Parnax Lab CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
40.60 INR
Jan 1, 2019
129.89 INR
Jan 1, 2020
150.72 INR
Jan 1, 2021
103.66 INR
Jan 1, 2022
208.62 INR
Jan 1, 2023
53.95 INR
Jan 1, 2024
204.66 INR
Jan 1, 2025
57.51 INR
The Parnax Lab CapEx/OCF history
YEARCapEx/OCFYoY
57.51 %-71.90%
204.66 %+279.38%
53.95 %-74.14%
208.62 %+101.24%
103.66 %-31.22%
150.72 %+16.04%
129.89 %+219.93%
40.60 %-56.75%
93.88 %-46.63%
175.89 %-111.64%
-1,510.59 %-60.66%
-3,839.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

CapEx to Operating Cash Flow Ratio of Parnax Lab is 57.51 % in 2025.

CapEx to Operating Cash Flow Ratio of Parnax Lab changed from 204.66 % to 57.51 %, representing a -71.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Parnax Lab with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Parnax Lab

All Key Metrics — Parnax Lab